HC Wainwright Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $35.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 155.29% from the stock’s previous close.

STOK has been the subject of a number of other research reports. Wedbush reaffirmed an “outperform” rating and set a $17.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.40.

Stoke Therapeutics Trading Down 7.0 %

Shares of STOK stock opened at $13.71 on Wednesday. The company’s fifty day moving average price is $14.35 and its 200-day moving average price is $12.83. The stock has a market cap of $721.83 million, a PE ratio of -5.69 and a beta of 0.96. Stoke Therapeutics has a 12 month low of $3.35 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The business had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.33 million. On average, sell-side analysts forecast that Stoke Therapeutics will post -2.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $13.75, for a total value of $137,500.00. Following the completion of the transaction, the insider now owns 2,485 shares in the company, valued at $34,168.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in STOK. Lynx1 Capital Management LP grew its position in Stoke Therapeutics by 40.3% in the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after purchasing an additional 1,488,371 shares during the period. Redmile Group LLC grew its holdings in shares of Stoke Therapeutics by 93.2% in the first quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock worth $68,486,000 after acquiring an additional 2,447,543 shares during the period. Baker BROS. Advisors LP increased its position in Stoke Therapeutics by 65.9% during the first quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock valued at $45,474,000 after acquiring an additional 1,338,309 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Stoke Therapeutics by 4.1% in the first quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock valued at $23,160,000 after acquiring an additional 67,052 shares during the period. Finally, Assenagon Asset Management S.A. bought a new position in Stoke Therapeutics in the second quarter valued at about $19,835,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.